CN113166232A - 使用增强的iPSC衍生效应细胞的免疫疗法 - Google Patents

使用增强的iPSC衍生效应细胞的免疫疗法 Download PDF

Info

Publication number
CN113166232A
CN113166232A CN201980079481.0A CN201980079481A CN113166232A CN 113166232 A CN113166232 A CN 113166232A CN 201980079481 A CN201980079481 A CN 201980079481A CN 113166232 A CN113166232 A CN 113166232A
Authority
CN
China
Prior art keywords
cells
cell
derived
receptor
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980079481.0A
Other languages
English (en)
Chinese (zh)
Inventor
B·瓦拉梅尔
R·比乔戴尔
T·T·李
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fate Therapeutics Inc
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of CN113166232A publication Critical patent/CN113166232A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
CN201980079481.0A 2018-12-02 2019-11-25 使用增强的iPSC衍生效应细胞的免疫疗法 Pending CN113166232A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862774278P 2018-12-02 2018-12-02
US62/774,278 2018-12-02
PCT/US2019/063024 WO2020117526A1 (en) 2018-12-02 2019-11-25 IMMUNOTHERAPIES USING ENHANCED iPSC DERIVED EFFECTOR CELLS

Publications (1)

Publication Number Publication Date
CN113166232A true CN113166232A (zh) 2021-07-23

Family

ID=70974390

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980079481.0A Pending CN113166232A (zh) 2018-12-02 2019-11-25 使用增强的iPSC衍生效应细胞的免疫疗法

Country Status (12)

Country Link
US (1) US12435123B2 (https=)
EP (1) EP3891177A4 (https=)
JP (2) JP2022510207A (https=)
KR (1) KR102943217B1 (https=)
CN (1) CN113166232A (https=)
AU (1) AU2019392265A1 (https=)
BR (1) BR112021010331A2 (https=)
CA (1) CA3121128A1 (https=)
IL (1) IL283607A (https=)
MX (1) MX2021006194A (https=)
SG (1) SG11202105480WA (https=)
WO (1) WO2020117526A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023093763A1 (en) * 2021-11-24 2023-06-01 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for cell-based immunotherapies cross-reference

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021292695A1 (en) * 2020-06-19 2023-02-02 Fate Therapeutics, Inc. Combining iPSC-derived effector cell types for immunotherapy use
CN114525255A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达il-11的多能干细胞衍生物及其应用
CA3196549A1 (en) * 2020-11-04 2022-05-12 Bahram Valamehr Engineered ipsc and immune effector cells for heterogenous tumor control
JP2023548467A (ja) * 2020-11-04 2023-11-17 フェイト セラピューティクス，インコーポレイティド 操作されたｉＰＳＣ及び持続性免疫エフェクター細胞
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
CA3204417A1 (en) * 2021-01-29 2022-08-04 Allogene Therapeutics, Inc. Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products
CN117615781A (zh) * 2021-02-25 2024-02-27 克莱格医学有限公司 Cd94工程化细胞及其组合物
US20220333074A1 (en) * 2021-04-07 2022-10-20 Century Therapeutics, Inc. Compositions and Methods for Generating Alpha-Beta T Cells from Induced Pluripotent Stem Cells
JP2024522756A (ja) * 2021-06-18 2024-06-21 オーエヌケイ セラピューティクス リミテッド ダブルノックアウトナチュラルキラー細胞
EP4353741A1 (en) * 2022-10-14 2024-04-17 ONK Therapeutics Limited Double knockout natural killer cells
WO2024183750A1 (en) * 2023-03-07 2024-09-12 Qihan Hong Kong Limited A novel immune cell and use thereof for treating diseases
WO2025189046A2 (en) * 2024-03-06 2025-09-12 The Johns Hopkins University Pantigen specific cytokine receptor stimulation of immune cell function

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1036327A2 (en) * 1997-12-04 2000-09-20 Isis Innovation Limited Hla-e binding
WO2007147898A1 (en) * 2006-06-22 2007-12-27 Novo Nordisk A/S Soluble heterodimeric receptors and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
US20040224385A1 (en) 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
WO2007146968A2 (en) 2006-06-12 2007-12-21 Trubion Pharmaceuticals, Inc. Single-chain multivalent binding proteins with effector function
HUE041436T2 (hu) 2009-12-10 2019-05-28 Univ Minnesota Tal-effektor-közvetített DNS-módosítás
EP3399026B1 (en) 2010-06-14 2024-06-26 The Scripps Research Institute Reprogramming of cells to a new fate
EP3549611B1 (en) 2011-07-29 2021-06-30 The Trustees of the University of Pennsylvania Switch costimulatory receptors
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
KR102437522B1 (ko) 2012-05-25 2022-08-26 셀렉티스 면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
EP4303232A3 (en) 2013-02-15 2024-04-17 The Regents of The University of California Chimeric antigen receptor and methods of use thereof
US9932607B2 (en) 2013-11-15 2018-04-03 The Board Of Trustees Of The Leland Stanford Junior University Site-specific integration of transgenes into human cells
US10934346B2 (en) 2014-02-14 2021-03-02 Bellicum Pharmaceuticals, Inc. Modified T cell comprising a polynucleotide encoding an inducible stimulating molecule comprising MyD88, CD40 and FKBP12
EP3656864A1 (en) 2014-02-14 2020-05-27 Board of Regents, The University of Texas System Chimeric antigen receptors and methods of making
SG11201606934SA (en) 2014-03-04 2016-09-29 Fate Therapeutics Inc Improved reprogramming methods and cell culture platforms
CN113699159A (zh) 2014-03-28 2021-11-26 明尼苏达大学评议会 涉及经工程改造的cd16的多肽、细胞和方法
US10888608B2 (en) 2014-09-02 2021-01-12 Bellicum Pharmaceuticals, Inc. Costimulation of chimeric antigen receptors by MyD88 and CD40 polypeptides
SG10202111851YA (en) 2015-10-16 2021-12-30 Fate Therapeutics Inc Platform for the Induction & Maintenance of Ground State Pluripotency
CA3003152A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
JP2019506143A (ja) 2015-12-14 2019-03-07 ベリカム ファーマシューティカルズ， インコーポレイテッド 治療用細胞の活性化及び排除のための二重コントロール
CA3010236A1 (en) * 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
CA3083779A1 (en) 2017-12-22 2019-06-27 Fate Therapeutics, Inc. Enhanced immune effector cells and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1036327A2 (en) * 1997-12-04 2000-09-20 Isis Innovation Limited Hla-e binding
WO2007147898A1 (en) * 2006-06-22 2007-12-27 Novo Nordisk A/S Soluble heterodimeric receptors and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EMILY CHIU: "Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)", 《BLOOD》, vol. 132, no. 1, 19 November 2018 (2018-11-19), pages 729, XP009527963, DOI: 10.1182/blood-2018-99-112202 *
MICHELLE L. LABONTE: "Molecular Determinants Regulating the Pairing of NKG2 Molecules with CD94 for Cell Surface Heterodimer Expression", 《THE JOURNAL OF IMMUNOLOGY》, vol. 172, no. 11, 6 January 2004 (2004-01-06), pages 6902 - 6912, XP055629905, DOI: 10.4049/jimmunol.172.11.6902 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023093763A1 (en) * 2021-11-24 2023-06-01 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for cell-based immunotherapies cross-reference

Also Published As

Publication number Publication date
AU2019392265A1 (en) 2021-06-03
US12435123B2 (en) 2025-10-07
EP3891177A4 (en) 2023-03-08
JP2025072543A (ja) 2025-05-09
EP3891177A1 (en) 2021-10-13
US20220127328A1 (en) 2022-04-28
KR20210099601A (ko) 2021-08-12
IL283607A (en) 2021-07-29
MX2021006194A (es) 2021-06-30
SG11202105480WA (en) 2021-06-29
KR102943217B1 (ko) 2026-03-25
CA3121128A1 (en) 2020-06-11
WO2020117526A1 (en) 2020-06-11
JP2022510207A (ja) 2022-01-26
BR112021010331A2 (pt) 2021-10-05

Similar Documents

Publication Publication Date Title
US11365394B2 (en) Enhanced immune effector cells and use thereof
JP7575271B2 (ja) 操作された免疫エフェクター細胞およびその使用
JP2025157281A (ja) 免疫エフェクター細胞操作およびその使用
CN113166232A (zh) 使用增强的iPSC衍生效应细胞的免疫疗法
JP2026041849A (ja) 複数標的化エフェクター細胞およびその使用
CN114761425A (zh) 用于免疫效应细胞工程化的增强的嵌合抗原受体和其用途
CN113906133A (zh) 工程改造的iPSC和免疫效应细胞中的CD3重建
CN114901693A (zh) 用于免疫效应细胞工程化的增强的嵌合抗原受体和其用途
CN115087731A (zh) 用小化合物增强iPSC衍生的效应免疫细胞
CN116096386A (zh) 组合iPSC衍生的效应细胞类型以用于免疫疗法用途
CA3196545A1 (en) Engineered ipsc and persistent immune effector cells
CN116615531A (zh) 用于异质肿瘤控制的工程改造的iPSC和免疫效应细胞
HK40051439A (en) Immunotherapies using enhanced ipsc derived effector cells
HK40063194A (en) Immune effector cell engineering and use thereof
HK40073230A (en) Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
HK40069004A (en) Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof
HK40111597A (zh) 效应细胞及其用於实体瘤中同种异体过继性细胞疗法的用途
HK40071271A (en) Multi-targeting effector cells and use thereof
HK40059448A (en) Cd3 reconstitution in engineered ipsc and immune effector cells
HK40096687A (zh) 工程改造的ipsc和持久性免疫效应细胞
HK40025663A (en) Enhanced immune effector cells and use thereof
HK40085484A (en) Combining ipsc-derived effector cell types for immunotherapy use
HK40033113A (en) Engineered immune effector cells and use thereof
HK40025098A (en) Immunotherapies using enhanced ipsc derived effector cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40051439

Country of ref document: HK